Clinical trial NCT05008562: How COVID-19 Effects to Muscle Mass Change ın ICU?
Official title: USG evaluatıon of COVID-19 Related Muscle Mass Change in the ICU
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: SARS-CoV-2 Acute Respiratory Disease
Sarcopenia
ICU Acquired Weakness
Critical Illness Myopathy
Keywords: Sarcopenia
ICU Acquired Weakness
SARS-CoV-2 Acute Respiratory Disease,
Lead sponsor: Ondokuz Mayıs University
Sponsor class: OTHER
First posted: 2021-08-17
Enrollment: 25
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Being in the Intensive Care Unit

* Over the age of 18
* Diagnosed with COVID-19 pneumonia

Brief summary: Critical illness myopathy and neuropathy are associated with prolonged mechanical ventilation, resulting in increased morbidity and mortality in intensive care units, .the investigators aimed to determine the decrease in muscle mass and risk factors that are important causes for the development of myopathy in COVID-19 (+) patients followed in intensive care unit. The study will also evaluate the relationships of patients withthe investigators intensive care-associated muscle weakness (ICU-AW) with other intensive care patient weight scores (SOFA, APACHE II, q SOFA).

Sensitivity of anthropometric measurements and ultrasonographic measurements will be compared in the evaluation of sarcopenia. The length of hospital stay, mechanical ventilation time, patient outcomes (mortality/morbidity) information of patients with COVID-19 pneumonia followed in the intensive care unit will be evaluated.

Detailed description: Sarcopenia (muscle weakness) is one of the geriatric syndromes that increases in frequency with age and is characterized by a decrease in muscle mass, strength and performance. Sarcopenia that occurs with aging is called primary sarcopenia, but sarcopenia can also occur due to secondary causes such as malnutrition, chronic diseases and immobility. One of the most important risk factors is advanced age. The prevalence of sarcopenia, which has been reported between 5% and 13% in a decade, can reach up to 50% over the age of 80. Sarcopenia is an important health problem that can cause loss of mobility, risk of functional dependence, risk of falling, increase in hospital stay, and consequently increase in morbidity and mortality, especially in elderly patients.

In order to be able to say sarcopenia, the investigators need to show that there is a decrease in muscle mass and, in addition, muscle strength and/or performance. Bio-electrical impedance analysis, anthropometric measurements or radiological measurements can be used among the most commonly used methods when evaluating muscle mass. However, there is no single gold standard measurement. Cross-sectional muscle area measurements, lean mass measurements and calf circumference measurements are the most commonly used muscle mass determination methods.

Ultrasonographic measurement of the rectus femoris muscle is a muscle mass measurement technique that has been used frequently recently. The most important measurement method used as a standard for muscle strength measurement is hand grip strength. The hand grip strength values reported for weakness acquired in the intensive care unit are at lower limits. \<11 kg in male patients and \<7 kg in female patients are considered significant limits for ICU-AW (intensive care unit-aquire weakness). However, there are some difficulties in evaluating muscle strength in intensive care patients. Most importantly, most of the patients are bedridden, immobile, receiving ventilation support, unable to cooperate, and who will not be conscious because they are under anesthesia. Apart from this, there are some measurement methods by sending magnetic or electrophysiological stimuli to the peripheral nerves in intensive care patients for muscle strength measurement, but they are mostly applied for clinical studies for now, due to the fact that they are invasive measurement methods and there are not enough equipped centers to apply them. In conclusion, sufficient number of studies examining this issue are required to reach a consensus on how to diagnose sarcopenia in intensive care patients.

In today's conditions, patients with a diagnosis of COVID-19 pneumonia are followed in the majority of intensive care units. In the study, patients with a diagnosis of COVID-19 followed in the intensive care unit will be evaluated. It is aimed to monitor, detect and investigate the factors affecting the muscle weakness of the disease, which the investigatorshave just met during the pandemic the investigators are in, and which causes different systemic involvement. There is no previous study on this subject in the literature.

Eligibility criteria: Inclusion Criteria:

* Being in the Intensive Care Unit

  * Over the age of 18
  * Diagnosed with COVID-19 pneumonia

Exclusion Criteria:

* Under the age of 18

  * Pregnancy
  * Having a cardiac pacemaker
  * Amputated lower limbs Having severe venous insufficiency or major injuries to their lower extremities
  * Having neuromuscular disease
  * Malignancy

Primary outcomes:
measure: Effects of COVID-19 ARDS on ICU-AW development, anthropometric measurement,
timeFrame: Change from baseline in thigh circumference at 21 days
measure: Effects of COVID-19 ARDS on ICU-AW development, ultrasonographic measurement
timeFrame: Change from baseline in thigh circumference at 21 days
measure: Effects of COVID-19 ARDS on ICU-AW development, scoring systems.
timeFrame: Change from baseline in thigh circumference at 21 days
measure: Effects of COVID-19 ARDS on ICU-AW development, scoring systems.
timeFrame: Change from baseline at 21 days
measure: Effects of COVID-19 ARDS on ICU-AW development, scoring systems.
timeFrame: Change from baseline at 21 days
measure: Effects of COVID-19 ARDS on ICU-AW development, scoring systems.
timeFrame: only first day
measure: Effects of COVID-19 ARDS on ICU-AW development, nutrition.
timeFrame: 21 days
Secondary outcomes:
Other outcomes:
Locations:
city: Istanbul
country: Turkey
facility: Gunes Comba Cebeci
state: Bayrampasa
Study officials:
References: